DOR/3TC/TDF doravirine/lamivudine/tenofovir DF
Standard DoseOne tablet once daily without regard to food for people taking HIV treatment for the first time (treatment-naïve) or individuals with a suppressed viral load on a stable HIV regimen for at least 6 months who have no known resistance to components of the regimen: doravirine, lamivudine, or tenofovir. Tablet contains 100 mg of the NNRTI doravirine plus 300 mg lamivudine and 300 mg tenofovir DF (TDF). Approved only for adults at this time.
Take missed dose as soon as possible, unless it is closer to the time of your next dose. Do not double up on your next dose. Dose cannot be adjusted for people with kidney problems; Delstrigo is not recommended in people with estimated creatinine clearance less than 50 mL/min. Should not be used in people with moderate or severe kidney impairment or severe liver impairment.
See the individual drugs contained in Delstrigo: Pifeltro, Viread, and Epivir.
See package insert for more complete information on potential side effects and interactions.
ManufacturerMerck and Co.
Potential Side Effects and Toxicity
The most common adverse reactions observed with Delstrigo in clinical trials of people taking it were dizziness (7%), nausea (5%), abnormal dreams (5%), and headache (4%). In one study (DRIVE-AHEAD), an in-depth analysis was conducted of the incidence of neuropsychiatric adverse events associated with Delstrigo compared to Atripla. Neuropsychiatric events, such as depression, sleep disturbances, dizziness, etc., are another common side effect of the NNRTI class. The proportion of subjects who reported one or more neuropsychiatric adverse events overall was 24% for the Delstrigo group compared to 57% for the Atripla group. The neuropsychiatric adverse events associated with depression and suicide/self-injury were reported in 4% of the Delstrigo group compared to 7% of the Atripla group. Overall, sleep disturbances (e.g., abnormal dreams, insomnia, nightmares, etc.) were associated with 12% of people in the Delstrigo group compared to 26% of people in the Atripla group. Dizziness was associated with 9% in the Delstrigo group compared to 37% of the Atripla group. Altered sensorium (e.g., lethargy, drowsiness, etc.) was associated with 4% of people in the Delstrigo group compared to 8% of people in the Atripla group. The doravirine component of Delstrigo did not appear to negatively affect cholesterol in studied populations. Decreases in bone mineral density (BMD) have been observed in patients on TDF-containing regimens. BMD monitoring should be considered in people who have a history of bone fracture due to bone disease or are at risk for osteopenia or osteoporosis. TDF may cause kidney toxicities. Creatinine clearance (CrCl) should be assessed before initiating treatment. In addition to CrCl, glucose and protein in the urine and serum phosphorus should be monitored more often in patients at risk for kidney problems. Tell your provider about any pain in extremities, persistent or worsening bone pain and fractures, with or without muscular pain or weakness, as well as any concerning changes in urinary habits, as these could be signs of kidney problems. If you have HIV and HBV, guidelines recommend treatment for both viruses. Delstrigo can be used to treat HIV and HBV simultaneously. If you are co-infected with HBV and HIV, you should not stop Delstrigo without medical supervision because it can cause your HBV to flare and cause you to experience signs and symptoms of acute hepatitis. HBV should be closely monitored by your provider.
Potential Drug Interactions
Do not take with Epivir-HBV, Hepsera, or Vemlidy (TAF), all three used for hepatitis B. When using with the antibiotic drug rifabutin (used for TB and to prevent MAC in AIDS patients), increase the doravirine dose by adding a Pifeltro tablet approximately 12 hours later. The following medications may lower the blood levels of doravirine, and therefore may decrease its effectiveness, and should not be used with Delstrigo: the anticonvulsants carbamazepine, oxcarbazepine, phenobarbital, and phenytoin; the androgen receptor inhibitor enzalutamide; the antimycobacterials rifampin and rifapentine; the cytotoxic agent (cancer drug) mitotane; and the herbal St. John’s wort. Avoid use of sorbitol-containing medicines with lamivudine; there are many, such as acetaminophen liquid (Tylenol liquid and others). Epclusa and Harvoni each increase the concentration of TDF; monitor for adverse reactions. Not intended to be taken with other HIV medications, unless prescribed that way. Tell your provider or pharmacist about all medications, herbals, and supplements you are taking or thinking of taking, prescribed or not, as there are other drug interactions which are not listed here.
Stand-alone versions of doravirine (Pifeltro) and lamivudine/tenofovir DF (Cimduo, Temixys) were also approved; see those pages. Unfortunately, Delstrigo contains an older version of tenofovir, TDF. A safer version, TAF, is available and used in some STRs. Ironically, however, as TAF and INSTIs may have some association with weight gain (see “Weighty Concerns,” beginning on page 8, and go to aidsinfo.nih.gov), Delstrigo may become a more popular option. TDF is still an effective and quite tolerable medication, but TAF has potentially less renal and bone toxicity. Doravirine has not been directly compared to integrase inhibitor-based regimens in clinical trials yet. There is no data on the safety of Delstrigo use in pregnancy.
In the DRIVE-FORWARD study comparing doravirine to darunavir, results for the treatment-naïve individuals in the study were 80% (darunavir group) and 84% (doravirine group) undetectable (less than 50 viral load).
Dr. Ross Slotten says:
Delstrigo, another STR, was approved by the FDA in August 2018. It has been described as a “quasi” generic because two of its components, TDF and 3TC (Epivir/lamivudine) are generic. Doravirine is a “second generation” NNRTI, distantly related to efavirenz. Delstrigo has earned a B1 rating from the DHHS, which means that it is moderately recommended and has been shown in non-randomized trials to be “non-inferior” to efavirenz- or darunavir-containing regimens. There have been no head-to-head clinical trials comparing this medication to INSTI-containing regimens. In terms of potency, it’s equivalent to many other HAART regimens. It contains TDF and not TAF. Currently, there is a class action lawsuit against Gilead, the manufacturer of TDF-containing regimens for “bone fracture” and “kidney injury.” Although, in my opinion, such a lawsuit is ridiculous, given that HIV medications have saved people’s lives and caused more good than harm, why would we now prescribe this medication as a first-line agent or a switch from another regimen when we have alternatives that either contain a TAF component or neither TAF nor TDF? Moreover, doravarine has a relatively low barrier to resistance and treatment-emergent resistance has been observed. I would classify this medication as a “C,” if asked, “C” meaning compelled by an insurance company for cost reasons only to prescribe it.
Activist Bridgette Picou says:
Delstrigo is a single-tablet regimen that can be taken with or without food. While it should not be used if there is moderate to severe kidney impairment, it seems otherwise tolerated well and considered safe. You should be tested for hepatitis B before starting or stopping this medication. If you are hep B-positive you can still take Delstrigo, but do not stop it suddenly or without notifying your provider as it may cause a harmful flare-up of your HBV infection. This medication can be used in both treatment-naïve (new starts) and treatment-experienced (stable regimen switch) individuals.